Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date

References

• WongPCPintoDJZhangDPreclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitorJ Thromb Thombolysis201131478492
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyEliquis [summary of product characteristics] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdfAccessed June 15, 2015
   Google Scholar
• Eliquis [prescribing information]Princeton (NJ)Bristol-Myers Squibb2015 Available from: http://packageinserts.bms.com/pi/pi_eliquis.pdfAccessed June 15, 2015
   Google Scholar
• European Medicines AgencyAssessment report for Eliquis Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002148/WC500107726.pdfAccessed June 15, 2015
   Google Scholar
• European Medicines AgencyAssessment report for Eliquis [variation]2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002148/WC500173870.pdfAccessed June 15, 2015
   Google Scholar
• European Medicines AgencyAssessment report for Eliquis [variation]2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002148/WC500136575.pdfAccessed June 15, 2015
   Google Scholar
• LevineMNGuCLiebmanHAA randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancerJ Thromb Haemost20121080781422409262
   PubMed Web of Science ®Google Scholar
• GoldhaberSZLeizoroviczAKakkarAJApixaban versus enox-aparin for thromboprophylaxis in medically ill patientsN Engl J Med20113652167217722077144
   PubMed Web of Science ®Google Scholar
• AlexanderJHBeckerRCBhattDLApixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trialCirculation20091192877288519470889
   PubMed Web of Science ®Google Scholar
• AlexanderJHLopesRDJamesSApixaban with antiplatelet therapy after acute coronary syndromeN Engl J Med201136569970821780946
   PubMed Web of Science ®Google Scholar
• OgawaHGotoSMatsuzakiMHiroSShimaDRandomized, double-blind trial to evaluate the safety of apixaban with antiplatelet therapy after acute coronary syndrome in Japanese patients (APPRAISE-J)Circ J2013772341234823748920
   PubMed Web of Science ®Google Scholar
• KonstantinidesSTorbickiAAgnelliG2014 ESC guidelines on the diagnosis and management of acute pulmonary embolismEur Heart J201435303330693069a3069k25173341
   PubMed Web of Science ®Google Scholar
• KearonCAklEComerotaAJAntithrombotic therapy for VTE diseaseChest2012141e419Se494S22315268
   PubMed Web of Science ®Google Scholar
• WongPCCrainEJXinBApixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studiesJ Thromb Haemost2008682082918315548
   PubMed Web of Science ®Google Scholar
• JiangXSCrainEJLuettgenJMSchumacherWAWongPCApixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitroThromb Haemost200810178078219350128
   PubMed Web of Science ®Google Scholar
• EscolarGFernandez-GallegoVArellano-RodrigoEReversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human bloodPloS One20138e7869624244342
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and ResearchApplication number 2012155Orig1s000. Clinical pharmacology and biopharmaceutics review(s)2012 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000ClinPharmR.pdfAccessed June 15, 2015
   Google Scholar
• Center for Drug Evaluation and ResearchApplication number 2012155Orig1s002. Clinical pharmacology and biopharmaceutics review(s)2013 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202155Orig1s002ClinPharmR.pdfAccessed June 15, 2015
   Google Scholar
• BarrettYCWangZFrostCShenkerAClinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assayThromb Haemost20101041263127120978714
   PubMed Web of Science ®Google Scholar
• BarrettYCWangJSongYA randomised assessment of the pharma-cokinetic, pharmacodynamics and safety interaction between apixaban and enoxaparin in healthy subjectsThromb Haemost201210791692422398784
   PubMed Web of Science ®Google Scholar
• CuiYSongYWangJSingle- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in Chinese subjectsClin Pharmacol2013517718424353445
   PubMedGoogle Scholar
• HannaMSMohanPKnabbRGuptaEFrostCLawrenceJHDevelopment of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillationAnn N Y Acad Sci201313299310625377080
   PubMed Web of Science ®Google Scholar
• FrostCWangJNepalSApixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjectsBr J Clin Pharmacol20127547648722759198
   PubMed Web of Science ®Google Scholar
• FrostCNepalSWangJSafety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjectsBr J Clin Pharmacol20137677678623451769
   PubMed Web of Science ®Google Scholar
• FrostCShenkerAGandhiMDEvaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixabanBr J Clin Pharmacol20147887788524697979
   PubMed Web of Science ®Google Scholar
• FrostCSongYBarrettYCA randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxabanClin Pharmacol2014617918725419161
   PubMedGoogle Scholar
• FrostCEByonWSongYEffect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitorBr J Clin Pharmacol20157983884625377242
   PubMed Web of Science ®Google Scholar
• FrostCSongYShenkerAEffects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixabanClin Pharmacokinet20155465166225573421
   PubMed Web of Science ®Google Scholar
• FrostCBoydRAThe contribution of apixaban renal clearance to total clearanceJ Thromb Thrombolysis20154052152225962516
   PubMed Web of Science ®Google Scholar
• FrostCNepalSByonWRandomized, blinded, placebo- and positive-controlled crossover study to determine the effect of multiple doses of apixaban on the QTc intervalJ Clin Pharmacol20155554955525501868
   PubMed Web of Science ®Google Scholar
• LeilTAFengYZhangLPaccalyAMohanPPfisterMQuantification of apixaban’s therapeutic utility in prevention of venous throm-boembolism: selection of phase III trial doseClin Pharmacol Ther20108837538220686477
   PubMed Web of Science ®Google Scholar
• RaghavanNFrostCEYuZGApixaban metabolism and pharmacokinetics after oral administration in humansDrug Metab Dispos200937748118832478
   PubMed Web of Science ®Google Scholar
• UpretiVVSongYWangJEffect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitorClin Pharmacol20135596623637566
   PubMedGoogle Scholar
• UpretiVVWangJBarrettYCEffect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjectsBr J Clin Pharmacol20137690891623488672
   PubMed Web of Science ®Google Scholar
• WangLRaghavanNHeKSulfation of O-demthyl apixaban: enzyme identification and species comparisonDrug Metab Dispos20093780280819131519
   PubMed Web of Science ®Google Scholar
• WangLZhangDRaghavanNIn vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition and induction studiesDrug Metab Dispos20103844845819940026
   PubMed Web of Science ®Google Scholar
• WangLHeKMaxwellBTissue distribution and elimination of [14C]apixaban in ratsDrug Metab Dispos20113925626421071521
   PubMed Web of Science ®Google Scholar
• WangXMondalSWangJEffect of activated charcoal on apixaban pharmacokinetics in healthy subjectsAm J Cardiovasc Drugs20141414715424277644
   PubMed Web of Science ®Google Scholar
• WongPCWatsonCACrainEJArterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbitsJ Thromb Haemost200861736174118647224
   PubMed Web of Science ®Google Scholar
• YamahiraNFrostCFukaseHSafety, tolerability, pharmacoki-netics and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjectsInt J Clin Pharmcol Ther201452564573
   PubMed Web of Science ®Google Scholar
• ZhangDHeKRaghavanNComparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs and humansDrug Metab Dispos2009371738174819420130
   PubMed Web of Science ®Google Scholar
• ZhangDFrostCEHeKInvestigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activate charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout ratsDrug Metab Dispos20134190691523386703
   PubMed Web of Science ®Google Scholar
• ZhangDHeKHerbstJJCharacterization of efflux transporters involved in distribution and disposition of apixabanDrug Metab Dispos20134182783523382458
   PubMed Web of Science ®Google Scholar
• LassenMRDavidsonBlGallusAPineoGAnsellJDeitchmanDThe efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacementJ Thromb Haemost200752368237517868430
   PubMed Web of Science ®Google Scholar
• LassenMRRaskobGEGallusAPineoGChenDPortmanRJApixaban or enoxaparin for thromboprophylaxis after knee replacementN Engl J Med200936159460419657123
   PubMed Web of Science ®Google Scholar
• LassenMRRaskobGEGallusAPineoGChenDHornickPApixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trialLancet201037580781520206776
   PubMed Web of Science ®Google Scholar
• LassenMRGallusARaskobGEPineoGChenDRamirezLMApixaban versus enoxaparin for thromboprophylaxis after hip replacementN Engl J Med20103632487249821175312
   PubMed Web of Science ®Google Scholar
• BullerHDeitchmanDPrinsMSegersAEfficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Boticelli DVT dose-ranging studyJ Thromb Haemost200861313131818541000
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAOral apixaban for the treatment of acute venous thromboembolismN Engl J Med201336979980823808982
   PubMed Web of Science ®Google Scholar
• AgnelliGBullerHRCohenAApixaban for extended treatment of venous thromboembolismN Engl J Med201336869970823216615
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCDefinition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patientsJ Thromb Haemost2005369269415842354
   PubMed Web of Science ®Google Scholar
• PineoGFGallusASRaskobGEApixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroupsJ Thromb Haemost20131144445123279103
   PubMed Web of Science ®Google Scholar
• TrkuljaVKolundžićRRivaroxaban vs dabigatran for thrombopro-phylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trialsCroat Med J20105111312320401953
   PubMed Web of Science ®Google Scholar
• HarenbergJMarxSDahlOEInterpretation of endpoints in a network meta-analysis of new oral anticoagulants following elective total hip or knee replacement surgeryThromb Haemost201210890391223014668
   PubMed Web of Science ®Google Scholar
• BacchusFSchulmanSClinical experience with the new oral anticoagulants for treatment of venous thromboembolismArterioscler Thromb Vasc Biol20153551351925717178
   PubMed Web of Science ®Google Scholar
• HirschlMKundiMNew oral anticoagulants in the treatment of acute venous thromboembolism – a systematic review with indirect comparisonsVasa20144335336425147012
   PubMed Web of Science ®Google Scholar
• KangNSobierajDMIndirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolismThromb Res20141331145115124713109
   PubMed Web of Science ®Google Scholar
• ManthaSAnsellJIndirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboem-bolismJ Thromb Thrombolysis20153915516524989022
   PubMed Web of Science ®Google Scholar
• CastellucciLACameronCLe GalGClinical and safety outcomes associated with treatment of acute venous thromboembolism : a systematic review and meta-analysisJAMA20143121122113525226478
   PubMed Web of Science ®Google Scholar
• SobierajDColemanCIPasupuletiVDeshapandeAKawRHernan-dezAVComparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysisThromb Res201513588889625795564
   PubMed Web of Science ®Google Scholar
• CastellucciLCameronCLe GalGEfficacy and safety of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysisBMJ2013347f513323996149
   PubMed Web of Science ®Google Scholar
• MahanCEPractical aspects of treatment with target specific anticoagulants: initiation, payment and current market, transitions, and venous thromboembolismJ Thromb Thrombolysis20153929530325605686
   PubMed Web of Science ®Google Scholar
• Gómez-OutesASuárez-GeaMLLecumberriRTerleira-FernándezAIVargas-CastrillónEDirect acting oral anticoagulants: pharmacology, indications, management and future perspectivesEur J Haematol20159538940426095540
   PubMed Web of Science ®Google Scholar
• WardCConnerGDonnanGGallusAMcRaeSPractical management of patients on apixaban: a consensus guideThromb J2013112724380488
   PubMedGoogle Scholar
• PollackCVJrCoagulation assessment with the new generation of oral anticoagulantsEmerg Med J2015018
   Google Scholar
• DouxfilsJManiHMinetVNon-VKA oral anticoagulants: accurate measurement of plasma drug concentrationsBiomed Res Int2015201534513826090400
   PubMed Web of Science ®Google Scholar
• EnriquezALipGYBaranchukAAnticoagulation reversal in the era of the non-vitamin K oral anticoagulantsEuropace Epub 2015 Mar 26
   Web of Science ®Google Scholar